FOLH1 and cancer: Taken together, given the limitations of a retrospective study with a potential selection bias, this single-center study including a substantial proportion of patients with treatment preference for Lu-PSMA in taxan-naïve mCRPC setting suggests Lu-PSMA therapy after previous ARPI treatment is associated with more favorable cancer-control outcomes compared to docetaxel and slightly better outcomes relative to ARPI treatment and may therefore be considered as an early treatment option in mCRPC.